It is intended to provide an inhibitor for the onset and/or progress of liver cancer for a patient with live cirrhosis who also has diabetes and/or has a BMI value of 25 or higher, comprising three types of branched amino acids i.e., isoleucine, leucine and valine, or salts thereof as active ingredients.